Hematologic Malignancies

Hematologic Malignancies

Genomic Markers May Predict Clinical Outcomes in Patients With B-Cell Acute Lymphoblastic Leukemia

Among adult patients with BCRABL1 negative B-ALL, genomic evaluation may lead to improved risk assessment, according to research published in Blood.

Hematology Advisor
COVID-19 Infection in Adult Patients With Hematological Malignancies

Baseline characteristics of HM patients developing COVID-19 were studied and analyzed as predictors of mortality.

Journal of Hematology & Oncology
Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Mutations that produce an alternative version of the protein created by the gene GNAS that can be targeted by drugs already approved by the FDA for treating other cancers...

Science Daily

Mutant NPM1-Regulated lncRNA HOTAIRM1 Promotes Leukemia Cell Autophagy and Proliferation by Targeting EGR1 and ULK3

Scientists investigate the functional and mechanistic roles of the lncRNA HOTAIRM1 to improve the diagnosis and treatment of patients with NPM1-mutated AML.

Journal of Experimental & Clinical Cancer Research
Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing

Scientists performed an analysis of scRNA-seq data of CNS tissue sequenced by 10x Genomics to identify the cell types of CNS cells.

Frontiers in Oncology
Mutation Analysis Links Angioimmunoblastic T-cell Lymphoma to Clonal Hematopoiesis and Smoking

Researchers explore the initiation and progression of AITL and PTCL-NOS to find the subset of AITL/PTCL-NOS patients that develop CHN and find a biomarker to predict this risk. 

Safety of a Bispecific Antibody in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Researchers aimed to determine the safety and tolerability of APVO436 in patients with R/R AML or MDS and to identify a recommended phase 2 dose (RP2D) level.

Hematology Advisor
Detailed Characterization of the Transcriptome of Single B Cells in Mantle Cell Lymphoma Suggesting a Potential Use for SOX4

Researchered investigated the transcriptome of MCL cells from eight diagnostic BM samples to provide insight into the complex and diverse molecular architecture of MCL at the single-cell transcript

Scientific Reports
Single-Cell RNA Sequencing Reveals Markers of Disease Progression in Primary Cutaneous T-cell Lymphoma

Scientists profiled patches with longstanding history, and compared them with recently developed plaques or tumors within the same patient to overcome inter-individual variability. 

Molecular Cancer
Differential Effects of Donor Lymphocyte Infusion Upon Treatment Response and GVHD According to Relapse Level and Donor Sources in Patients With Myelodysplastic Syndrome

In this study, investigators analyzed 61 consecutive myelodysplastic syndrome and secondary AML patients receiving DLI for the control of post-SCT relapse.

Therapeutic Advances in Hematology
Hypomethylating Agents and FLT3 Inhibitors as Maintenance Treatment for AML and Myelodysplastic Syndrome Following Allogeneic Hematopoietic Stem Cell Transplant

This study aims to synthesize the current evidence on the efficacy and safety of FLT3 inhibitors and HMA for maintenance therapy following allo-HCT in AML and MDS.

Transplantation and Cellular Therapy
Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

Researchers retrospectively compared SAA that had progressed from NSAA in patients undergoing first-line IST (n=229) with patients meeting the criteria for SAA at the time of diagnosis (n=232)...

Frontiers in Oncology
Bortezomib and Rituximab in de novo Adolescent/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukemia

Scientists evaluate the activity of this combination during induction in adolescents and adults with CD20+ Ph– precursor B-ALL...

Blood Advances
Inhibiting DNA Repair in Hematologic Malignancies & Solid Tumors

Researchers evaluating the safety and efficacy of CYT-0851 find the first-in-class small molecule inhibitor of RAD51-mediated DNA repair is well-tolerated by patients and has promising anti-tumor..

Oncology Times - Latest Articles
The Safety of the COVID-19 Vaccine for Blood Cancer Patients

About one in four blood cancer patients fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a new study...

Oncology Times - Latest Articles
Mechanism of Leukemia Pathogenesis & Possible Targeted Therapy

In a new research paper, scientists describe how molecular mechanisms of the ASXL1 gene mutation are involved in leukemia pathogenesis, and they also identify a possible targeted therapy for...

Oncology Times - Latest Articles
Study Explores Relationship Between Anti-CD20 Therapy and Reduced Responses to mRNA COVID-19 Vaccines

Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease.

The ASCO Post
Benign and Malignant Hematologic Manifestations in Patients With VEXAS Syndrome Due to Somatic Mutations in UBA1

Patients with VEXAS syndrome have a propensity toward developing cytopenia, MDS, multiple myeloma, and venous thromboembolism.

Blood Advances
Second-Line CAR-T Fails to Extend EFS in Aggressive B-cell Non-Hodgkin Lymphoma

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell NHL failed to meet its primary endpoint of improved EFS

CHIP May Affect Some Outcomes in Patients Receiving CAR T-Cell Therapy

Clonal hematopoiesis of indeterminate potential is associated with some outcomes of CAR T-cell therapy, according to research published in Blood Advances.

Cancer Therapy Advisor
Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL

Study investigators find that donor-derived CD7 CAR T-cell therapy produces a high complete remission rate in patients with R/R T-cell acute lymphoblastic leukemia.

The ASCO Post
Single-Nucleotide Fcγ Receptor Polymorphisms Do Not Impact Obinutuzumab/Rituximab Outcome in Patients With Lymphoma

FcγR genotype is not associated with response to obinutuzumab/rituximab combined with chemotherapy in untreated patients with FL or DLBCL.

Blood Advances
Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia

The aim of this study is to investigate the efficacy and safety of low-dose decitabine on the prevention of adult ALL relapse after allo-HSCT.

Frontiers in Oncology
Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

CAR T-cell therapy has exhibited promising clinical outcomes in treating relapsed/refractory B-cell hematologic malignancies.

Frontiers in Oncology
Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma

The addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone significantly improves OS over lenalidomide/dexamethasone alone..

The ASCO Post
Blood Cancer Patients With COVID-19 Fare Better With Convalescent Plasma

A large, retrospective, multicenter study indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients...

Oncology Times - Latest Articles
Understanding Tolerance for Imatinib Nonadherence Among CML Patients

New analyses from the ADAGIO study presented at the ASCO 2021 Annual Meeting challenge the tolerance for nonadherence to imatinib among patients with chronic myeloid leukemia.

Oncology Times - Latest Articles
Recovery of Gonadal Function With PET-Adapted Regimen for Advanced Hodgkin Lymphoma

Demeestere et al find that patients with advanced Hodgkin lymphoma receiving a PET-adapted regimen have a reduced risk of gonadal dysfunction vs standard CT.

The ASCO Post
HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia

In the present study, investigators reveal that HNRNPH1 expression level is upregulated in CML patients and cell lines.

Frontiers in Oncology
Toxicities of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Older Patients With Lymphoma

Cardiovascular toxicities are higher in older patients, but nonrelapse mortality at 100 days and 1 year is comparable to younger patients.

Blood Advances
Brexucabtagene Autoleucel in Adults With Relapsed or Refractory B-Cell ALL: ZUMA-3

The pivotal phase II ZUMA-3 trial has shown a high rate of complete remission with the autologous anti-CD19 CAR T-cell therapy brexucabtagene autoleucel in adults with R/R B-cell acute lymphoblasti

The ASCO Post
Prolonged COVID-19 Common Among Patients With Lymphoma

Patients with B-cell non-Hodgkin lymphoma who are hospitalized for COVID-19 are at high risk of developing prolonged COVID-19.

Luspatercept Benefit Also in Non-Transfusion-Dependent Thalassemia

The first-in-class erythroid maturation agent luspatercept is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell transfusions.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)